Literature DB >> 19581563

Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder.

Becky Inkster1, Thomas E Nichols, Philipp G Saemann, Dorothee P Auer, Florian Holsboer, Pierandrea Muglia, Paul M Matthews.   

Abstract

CONTEXT: Indirect evidence suggests that the glycogen synthase kinase-3beta (GSK3beta) gene might be implicated in major depressive disorder (MDD).
BACKGROUND: We evaluated 15 GSK3beta single-nucleotide polymorphisms (SNPs) to test for associations with regional gray matter (GM) volume differences in patients with recurrent MDD. We then used the defined regions of interest based on significant associations to test for MDD x genotype interactions by including a matched control group without any psychiatric disorder, including MDD.
DESIGN: General linear model with nonstationary cluster-based inference.
SETTING: Munich, Germany. PARTICIPANTS: Patients with recurrent MDD (n = 134) and age-, sex-, and ethnicity-matched healthy controls (n = 143). MAIN OUTCOME MEASURES: Associations between GSK3beta polymorphisms and regional GM volume differences.
RESULTS: Variation in GM volume was associated with GSK3beta polymorphisms; the most significant associations were found for rs6438552, a putative functional intronic SNP that showed 3 significant GM clusters in the right and left superior temporal gyri and the right hippocampus (P < .001, P = .02, and P = .02, respectively, corrected for multiple comparisons across the whole brain). Similar results were obtained with rs12630592, an SNP in high linkage disequilibrium. A significant SNP x MDD status interaction was observed for the effect on GM volumes in the right hippocampus and superior temporal gyri (P < .001 and P = .01, corrected, respectively).
CONCLUSIONS: The GSK3beta gene may have a role in determining regional GM volume differences of the right hippocampus and bilateral superior temporal gyri. The association between genotype and brain structure was specific to the patients with MDD, suggesting that GSK3beta genotypes might interact with MDD status. We speculate that this is a consequence of regional neocortical, glial, or neuronal growth or survival. In considering core cognitive features of MDD, the association of GSK3beta polymorphisms with structural variation in the temporal lobe and hippocampus is of particular interest in the context of other evidence for structural and functional abnormalities in the hippocampi of patients with MDD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581563     DOI: 10.1001/archgenpsychiatry.2009.70

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  40 in total

Review 1.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

2.  Cognitive function in acromegaly: description and brain volumetric correlates.

Authors:  Caroline Sievers; P G Sämann; H Pfister; C Dimopoulou; M Czisch; J Roemmler; J Schopohl; G K Stalla; J Zihl
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 3.  Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.

Authors:  Jason M Dwyer; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-01-04       Impact factor: 13.382

Review 4.  Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior.

Authors:  Syed Mohammed Qasim Hussaini; Chan-Il Choi; Chang Hoon Cho; Hyo Jin Kim; Heechul Jun; Mi-Hyeon Jang
Journal:  Neurosci Biobehav Rev       Date:  2014-09-28       Impact factor: 8.989

5.  Meta-analysis demonstrates lack of association of the GSK3B -50C/T polymorphism with risk of bipolar disorder.

Authors:  Guodi Chen; Jun Tang; Guangwei Yu; Yiping Chen; Liancong Wang; Yao Zhang
Journal:  Mol Biol Rep       Date:  2014-06-15       Impact factor: 2.316

6.  Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation.

Authors:  Shusuke Numata; Kazuo Ishii; Atsushi Tajima; Jun-ichi Iga; Makoto Kinoshita; Shinya Watanabe; Hidehiro Umehara; Manabu Fuchikami; Satoshi Okada; Shuken Boku; Akitoyo Hishimoto; Shinji Shimodera; Issei Imoto; Shigeru Morinobu; Tetsuro Ohmori
Journal:  Epigenetics       Date:  2015-01-14       Impact factor: 4.528

Review 7.  Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents.

Authors:  Ronald S Duman; Bhavya Voleti
Journal:  Trends Neurosci       Date:  2012-01       Impact factor: 13.837

8.  Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.

Authors:  Francesco Benedetti; Sara Poletti; Daniele Radaelli; Clara Locatelli; Adele Pirovano; Cristina Lorenzi; Benedetta Vai; Irene Bollettini; Andrea Falini; Enrico Smeraldi; Cristina Colombo
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

9.  Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: a study using the stanley neuropathology consortium integrative database.

Authors:  Dong Hoon Oh; Yong Chon Park; Seok Hyeon Kim
Journal:  Psychiatry Investig       Date:  2010-07-12       Impact factor: 2.505

10.  GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.

Authors:  Hui Tang; Na Shen; Huijuan Jin; Dan Liu; Xiaoping Miao; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2013-02-27       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.